Bionor to present anticipated next steps to value creation at its Capital Markets Day in Oslo today
(Oslo, Norway, 7 October 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a Norwegian biopharmaceutical company focused on developing its proprietary therapeutic vaccine Vacc-4x for HIV, will today host a Capital Markets Day for institutional and private investors and financial analysts from 12:00-15:30 CEST at the Hotel Continental, Stortingsgata 24-26, 0117 Oslo, Norway.
The objective of the Capital Markets Day is to discuss and create a fundamental, common understanding of the value proposition associated with Bionor’s first mover potential to advance a possible functional HIV cure with Vacc-4x at its core, by presenting key clinical results to date, Bionor’s revitalized strategic focus on Vacc-4x and its current development strategy.
Bionor’s strategic intent is to advance Vacc-4x in combination with other medicines toward major value inflection points in order to contribute to the development of a possible functional HIV cure. Bionor believes that it is well positioned to advance Vacc-4x to expected major value inflection points, based on:
- First mover potential to advance a possible functional cure based on clinical results to date and early adoption of “Shock & Kill” clinical strategy
- A large unmet medical need among HIV patients
- A clear development strategy for the Company’s key asset with credible steps taken to drive value beyond the REDUC clinical trial
- A strong board and management team to bring the strategy to life
- Having full proprietary rights to Vacc-4x, i.e., upside potential from partnering or licensing remain with the company’s shareholders
- An extensive network among recognized HIV experts and Key Opinion Leaders to attract investigators and patients, and to increase awareness of the company
Anticipated next steps to value creation - The BIOSKILL Phase II clinical trial
With reference to Bionor’s 12 August 2015 half-year report, the Company is currently planning a multi-center randomized, double-blind, placebo-controlled Phase II proof of concept clinical trial with the aim to investigate the contribution of Vacc-4x as a component in a functional cure for HIV, together with a latency reversing agent. The trial has now been named BIOSKILL (BIOnor Shock and Kill).
Capital Markets Day agenda
12:45: Welcome – David Solomon, CEO
12:50: The New Bionor – Russell Greig, Chairman
13:00: Bionor at a glance – David Solomon, CEO
13:20: Understanding HIV – Alejandra Mørk, Acting Head of Development
13:50: HIV Cure – Lars Østergaard, MD, PhD, DMSc, Aarhus University Hospital
14:20: Anticipated next steps to value creation – David Solomon, CEO
14:50: Q&A Session
15:20: Closing remarks – David Solomon, CEO
Webcast and presentation
The event will be webcast live and can be accessed through the following link: http://webtv.hegnar.no/presentation.php?webcastId=25220408.
The presentations are published with this announcement and will be available on Bionor’s website. A webcast replay will be available on the company’s website after the event.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on developing its proprietary therapeutic vaccine, Vacc-4x, for human immunodeficiency virus (HIV), which, if left untreated, causes acquired immunodeficiency syndrome, (AIDS), in humans. Bionor Pharma has first mover potential to advance its therapeutic vaccine, Vacc-4x, in combination with other medicines, as part of a functional cure for HIV. Vacc-4x has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the latency reversing agent romidepsin in the REDUC study. Bionor is headquartered in Oslo, Norway, and is listed on the Oslo stock exchange, under the ticker BIONOR. More information about Bionor is available at www.bionorpharma.com.